Brokerages Set TG Therapeutics, Inc. (NASDAQ:TGTX) Target Price at $40.67

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $40.67.

A number of brokerages recently commented on TGTX. JPMorgan Chase & Co. boosted their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, January 31st. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price target on the stock. Finally, The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th.

Insider Activity

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now directly owns 670,632 shares of the company's stock, valued at $20,313,443.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of TGTX. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 485 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in shares of TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares during the period. Jones Financial Companies Lllp raised its holdings in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in TG Therapeutics in the third quarter valued at about $53,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Down 3.5 %

TG Therapeutics stock traded down $1.14 during trading on Friday, reaching $31.11. The stock had a trading volume of 1,250,089 shares, compared to its average volume of 2,365,188. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics has a 52-week low of $12.84 and a 52-week high of $36.84. The stock has a market cap of $4.84 billion, a PE ratio of -311.07 and a beta of 2.26. The business has a 50 day moving average price of $31.33 and a 200 day moving average price of $27.18.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.